, Supplementary Materials: Supplementary materials can be

A. Guenther, E. Krauss, S. Tello, J. Wagner, B. Paul et al., The European IPF registry (eurIPFreg): Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis, Respir. Res, vol.19, p.141, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02006205

N. Galie, M. Humbert, J. L. Vachiery, S. Gibbs, I. Lang et al., ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the, ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), vol.46, pp.903-975, 2015.

J. A. Kropski, W. E. Lawson, L. R. Young, and T. S. Blackwell, Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis, Dis. Model. Mech, vol.6, pp.9-17, 2013.

E. Bargagli, C. Olivieri, N. Nikiforakis, M. Cintorino, B. Magi et al., Analysis of macrophage migration inhibitory factor (MIF) in patients with idiopathic pulmonary fibrosis, Respir. Physiol. Neurobiol, vol.167, pp.261-267, 2009.

C. Olivieri, E. Bargagli, S. Inghilleri, I. Campo, M. Cintorino et al., Macrophage migration inhibitory factor in lung tissue of idiopathic pulmonary fibrosis patients, Exp. Lung Res, vol.42, pp.263-266, 2016.

Y. Tanino, H. Makita, K. Miyamoto, T. Betsuyaku, Y. Ohtsuka et al., Role of macrophage migration inhibitory factor in bleomycin-induced lung injury and fibrosis in mice, Am. J. Physiol. Lung Cell. Mol. Physiol, vol.283, pp.156-162, 2002.

C. Corallo, L. Paulesu, M. Cutolo, F. Ietta, C. Carotenuto et al., Serum levels, tissue expression and cellular secretion of macrophage migration inhibitory factor in limited and diffuse systemic sclerosis, Clin. Exp. Rheumatol, vol.33, pp.98-105, 2015.

L. Hiress, M. Akagah, B. Bernadat, G. Tu, L. Thuillet et al., Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension, J. Med. Chem, vol.61, pp.2725-2736, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02580381

L. Hiress, M. Tu, L. Ricard, N. Phan, C. Thuillet et al., Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex, Am. J. Respir. Crit. Care Med, vol.192, pp.983-997, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02579320

P. Bonniaud, A. Fabre, N. Frossard, C. Guignabert, M. Inman et al., Optimising experimental research in respiratory diseases: An ERS statement, Eur. Respir. J, vol.51, p.1702133, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01996906

A. Moeller, K. Ask, D. Warburton, J. Gauldie, and M. Kolb, The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?, Int. J. Biochem. Cell. Biol, vol.40, pp.362-382, 2008.

G. Borzone, R. Moreno, R. Urrea, M. Meneses, M. Oyarzun et al., Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis, Am. J. Respir. Crit. Care Med, vol.163, pp.1648-1653, 2001.

C. J. Schaefer, D. W. Ruhrmund, L. Pan, S. D. Seiwert, and K. Kossen, Antifibrotic activities of pirfenidone in animal models, Eur. Respir. Rev, vol.20, pp.85-97, 2011.

L. Wollin, I. Maillet, V. Quesniaux, A. Holweg, and B. Ryffel, Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis, J. Pharmacol. Exp. Ther, vol.349, pp.209-220, 2014.

L. Farkas, D. Farkas, K. Ask, A. Moller, J. Gauldie et al., VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats, J. Clin. Investig, vol.119, pp.1298-1311, 2009.

B. Zhang, M. Shen, M. Xu, L. L. Liu, Y. Luo et al., Role of macrophage migration inhibitory factor in the proliferation of smooth muscle cell in pulmonary hypertension, Mediators Inflamm, vol.840737, 2012.

Y. Zhang, A. Talwar, D. Tsang, A. Bruchfeld, A. Sadoughi et al., Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension, Mol. Med, vol.18, pp.215-223, 2012.

G. Izbicki, M. J. Segel, T. G. Christensen, M. W. Conner, and R. Breuer, Time course of bleomycin-induced lung fibrosis, Int. J. Exp. Pathol, vol.83, pp.111-119, 2002.

S. L. Deshmane, S. Kremlev, S. Amini, and B. E. Sawaya, Monocyte chemoattractant protein-1 (MCP-1): An overview, J. Interferon Cytokine Res, vol.29, pp.313-326, 2009.

M. Colombat, H. Mal, O. Groussard, F. Capron, G. Thabut et al., Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: Histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics, Hum. Pathol, vol.38, pp.60-65, 2007.

S. Gunther, P. Fagone, G. Jalce, A. Atanasov, C. Guignabert et al., Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: From pathogenic factors to therapeutic targets, Drug Discov. Today, 2018.

A. Bruchfeld, J. J. Carrero, A. R. Qureshi, B. Lindholm, P. Barany et al., Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation, Mol. Med, vol.15, pp.70-75, 2009.

H. Lu, Y. Bai, L. Wu, W. Hong, Y. Liang et al., Inhibition of Macrophage Migration Inhibitory Factor Protects against Inflammation and Matrix Deposition in Kidney Tissues after Injury, Mediators Inflamm, 2016.

G. Ningyan, Y. Xu, S. Hongfei, C. Jingjing, and C. Min, The role of macrophage migration inhibitory factor in mast cell-stimulated fibroblast proliferation and collagen production, PLoS ONE, vol.10, 2015.

L. Bossini-castillo, D. Campillo-davo, E. Lopez-isac, F. D. Carmona, C. P. Simeon et al., An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis, J. Rheumatol, vol.44, pp.1453-1457, 2017.

J. Bloom, S. Sun, and Y. Al-abed, MIF, a controversial cytokine: A review of structural features, challenges, and opportunities for drug development, Expert Opin. Ther. Targets, vol.20, pp.1463-1475, 2016.

G. Pantouris, M. A. Syed, C. Fan, D. Rajasekaran, T. Y. Cho et al., An Analysis of MIF Structural Features that Control Functional Activation of CD74, Chem. Biol, vol.22, pp.1197-1205, 2015.

D. Rajasekaran, S. Groning, C. Schmitz, S. Zierow, N. Drucker et al., Macrophage Migration Inhibitory Factor-CXCR4 Receptor Interactions: Evidence for Partial Allosteric Agonism in Comparison with CXCL12 Chemokine, J. Biol. Chem, vol.291, pp.15881-15895, 2016.

Y. Al-abed and S. Vanpatten, MIF as a disease target: ISO-1 as a proof-of-concept therapeutic, Future Med. Chem, vol.3, pp.45-63, 2011.

J. A. Cisneros, M. J. Robertson, M. Valhondo, and W. L. Jorgensen, Irregularities in enzyme assays: The case of macrophage migration inhibitory factor, Bioorg. Med. Chem. Lett, vol.26, pp.2764-2767, 2016.

V. Trivedi-parmar and W. L. Jorgensen, Advances and Insights for Small Molecule Inhibition of Macrophage Migration Inhibitory Factor, J. Med. Chem, 2018.

R. Kleemann, A. Hausser, G. Geiger, R. Mischke, A. Burger-kentischer et al., Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1, Nature, vol.408, pp.211-216, 2000.

G. Raghu, M. Remy-jardin, J. L. Myers, L. Richeldi, C. J. Ryerson et al., Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline, Am. J. Respir. Crit. Care Med, vol.198, pp.44-68, 2018.

C. Guignabert, C. Phan, A. Seferian, A. Huertas, L. Tu et al., Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension, J. Clin. Investig, vol.126, pp.3207-3218, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02579754

A. Huertas, L. Tu, R. Thuillet, M. Le-hiress, C. Phan et al., Leptin signalling system as a target for pulmonary arterial hypertension therapy, Eur. Respir. J, vol.45, pp.1066-1080, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02579431

C. Phan, E. M. Jutant, L. Tu, R. Thuillet, A. Seferian et al., Vonk Noordegraaf, A.; et al. Dasatinib increases endothelial permeability leading to pleural effusion, Eur. Respir. J, vol.51, 2018.

Y. Tamura, C. Phan, L. Tu, M. Le-hiress, R. Thuillet et al., Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension, J. Clin. Investig, vol.128, 1956.
URL : https://hal.archives-ouvertes.fr/inserm-02580448

L. Tu, F. S. De-man, B. Girerd, A. Huertas, M. C. Chaumais et al., A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents, Am. J. Respir. Crit. Care Med, vol.186, pp.666-676, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00905191

T. Guilbert, C. Odin, Y. Le-grand, L. Gailhouste, B. Turlin et al., A robust collagen scoring method for human liver fibrosis by second harmonic microscopy, Opt. Express, vol.18, pp.25794-25807, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00684532

F. S. De-man, L. Tu, M. L. Handoko, S. Rain, G. Ruiter et al., Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension, Am. J. Respir. Crit. Care Med, vol.186, pp.780-789, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-00905193

L. Tu, L. Dewachter, B. Gore, E. Fadel, P. Dartevelle et al., Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension, Am. J. Respir. Cell. Mol. Biol, vol.45, pp.311-322, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00579959